Navigation Links
US FDA Grants Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness
Date:9/19/2007

NEW YORK, Sept. 19 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pafuramidine (DB289) for treating Human African Trypanosomiasis (HAT), also known as African sleeping sickness. Orphan drug designation provides Immtech with numerous financial and regulatory benefits during pafuramidine's development, including government grants for conducting clinical trials, waiver of New Drug Application submission fees, tax credits, and a seven-year market exclusivity upon final FDA approval.

Pafuramidine is currently in phase III clinical trials for African sleeping sickness at six trial sites in Africa. The infectious disease, spread by tsetse flies, threatens approximately 60 million people in over 30 countries in sub-Saharan Africa. Current treatments for the disease are associated with high levels of toxicity and are difficult to administer. Safety data for pafuramidine has been positive to date, and the FDA and Ethics Committees responsible for the study oversight currently allow adolescents, pregnant women and nursing mothers to participate in these clinical trials. These groups are particularly vulnerable to the disease.

"The FDA's decision reflects the significant need for new treatments for African sleeping sickness," stated Carol Olson, MD, PhD, Immtech's Sr. Vice President and Chief Medical Officer. "Pafuramidine has the potential to be the first oral treatment for this fatal and neglected disease. Patients often put off screening and treatment because current drugs must be given by injection. A safe and effective pill that is readily available should facilitate cure for more patients i
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
5. Point of Care Strep Tests Speed Treatment, Lower Costs
6. Rapid HIV Testing Increases Possibility of Treatment
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)... -- Larry J. Merlo , President and CEO of ... the National Press Club in Washington, D.C. ... stop selling tobacco products and its leadership in driving the ... "Dramatic changes in our health care system pose enormous challenges ... said. "CVS Health has a truly unique combination of business ...
(Date:9/19/2014)... Sept. 19, 2014  Alere Inc. (NYSE: ... the following statement today in support of President ... "As the global leader in rapid diagnostics for ... national strategy to address the serious threat of antibiotic ... the Administration on initiatives to promote the development of ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... Ability of Adecatumumab to Prolong Disease Free Survival ... March 23 Micromet, Inc. (Nasdaq: ... novel, proprietary antibodies for the treatment of cancer, ... of a randomized, controlled phase 2 trial of ...
... announced today that,the fourth LNA-based drug has been ... with cancer have now been treated with the ... Pharma and Enzon,Pharmaceuticals. The U.S. Food and Drug ... (IND) application,for the use of the LNA-based Survivin ...
Cached Medicine Technology:Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 2Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 3Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 4Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients 5Another LNA-based RNA Inhibitor Enters Clinical Trials 2Another LNA-based RNA Inhibitor Enters Clinical Trials 3
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
(Date:9/19/2014)... By Alan Mozes ... (HealthDay News) -- Cancer patients burdened by stress and ... for complications following their operation, a new study suggests. ... "deficit" appeared to have a nearly three times greater ... or good quality of life. "We,ve long known ...
(Date:9/19/2014)... PA (PRWEB) September 19, 2014 "I ... fear getting wrinkles due to stretching the skin around ... Anniston, Ala. "This inspired me to design a more ... EYE CONTACT LENS SYSTEM provides a quicker, easier, more ... the need to perform this task manually, saves time ...
(Date:9/19/2014)... Mayo Clinic have discovered a defect in a key ... toxic protein in the brains of Alzheimer,s disease ... neurons both significant contributors to this type of ... Neuron , offers the potential that ... rescue this pathway," says the study,s lead investigator, ...
(Date:9/19/2014)... 19, 2014 Recently, Top10BestSEOHosting.com has ... that JustHost, IX Web Hosting and Bluehost are ... “As is known to most people, VPS (Virtual ... physical server computer into many servers, each of ... on someone’s own dedicated computer,” the manager of ...
Breaking Medicine News(10 mins):Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2
... , PHILADELPHIA (June 14, 2011) Fox Chase Cancer ... treatment institutions, today announced it has entered into an ... new program to provide next-generation sequencing analysis of solid ... the planned Cancer Genome Institute at Fox Chase, a ...
... can help college students retain and integrate new information ... research abstract that will be presented Tuesday, June 14, ... Meeting of the Associated Professional Sleep Societies LLC (APSS). ... a microeconomics test was preserved after a 12-hour period ...
... duration may contribute to the development or worsening ... a research abstract that will be presented Tuesday, ... the 25th Anniversary Meeting of the Associated Professional ... less sleep in preschool-age children significantly predicted worse ...
... cutting-edge research that promises to revolutionise the diagnosis and treatment ... used in the long-term to develop a radical new type ... dummy to meet the different needs of individual patients. If ... market within 4 years. The research is being ...
... MONDAY, June 13 (HealthDay News) -- Playing a memory-straining video ... that can be difficult to achieve through so-called cognitive training, ... ordinary video games have this kind of power. But it ... brain skills even months later, said study author Susanne M. ...
... BROOK, Ill. June 13, 2011 A ... bowel preparation are associated with relatively high adenoma ... preparation substantially decreases colonoscopy effectiveness and may mandate ... the context of suboptimal bowel preparation, of all ...
Cached Medicine News:Health News:Fox Chase Cancer Center signs agreement with Life Technologies Corp. 2Health News:Fox Chase Cancer Center signs agreement with Life Technologies Corp. 3Health News:Sleep can boost classroom performance of college students 2Health News:Sleep loss in early childhood may contribute to the development of ADHD symptoms 2Health News:New software 'hearing dummies' pave the way for tailor-made hearing aids 2Health News:New software 'hearing dummies' pave the way for tailor-made hearing aids 3Health News:Training via Video Game Shown to Boost Kids' Brain Power 2Health News:Training via Video Game Shown to Boost Kids' Brain Power 3Health News:Polyp miss rates high for colonoscopies done after poor bowel preparation 2Health News:Polyp miss rates high for colonoscopies done after poor bowel preparation 3Health News:Polyp miss rates high for colonoscopies done after poor bowel preparation 4
... The Laserex Ultra Q is the fundamental ... cavity optimizes energy delivery and provides 2855% less ... to 2.54.0 mJs in contemporary systems. This ... dramatically reduces the risk of IOL pitting. ...
... The Ultrasonix 500 is a high-end, mobile ... based architecture provides a tremendous amount of ... contrast and resolution. Ultrasonix imaging systems ... modes including B, B/M, Pulsed Doppler, Color ...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see....
Protects the eye during or after surgery or trauma. 8mm diameter, lint free keeps cornea moist. Protects retina from operating microscope light rays....
Medicine Products: